Form 8-K

8-K — NEUROONE MEDICAL TECHNOLOGIES Corp

Accession: 0001213900-26-094174

Filed: 2026-08-27

Period: 2026-08-27

CIK: 0001500198

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0303530-8k_neuroone.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED AUGUST 27, 2026 (ea030353001ex99-1.htm)

GRAPHIC (ea030353001_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0303530-8k_neuroone.htm · Sequence: 1

false

0001500198

2026-08-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of Earliest Event Reported): August 27, 2026

NeuroOne Medical Technologies Corporation

(Exact

name of registrant as specified in its charter)

Delaware

001-40439

27-0863354

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address

of principal executive offices and zip code)

952-426-1383

(Registrant’s

telephone number including area code)

(Registrant’s

former name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, par value $0.001 per share

NMTC

The Nasdaq Stock Market

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

Growth Company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01 Other Events.

August 27, 2026, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing that three procedures

in large animals were performed using the Company’s StereoCED™ platform. A copy of the above referenced press release is

filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release, dated August 27, 2026

104

Cover Page Interactive Data File (embedded with Inline

XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

NEUROONE

MEDICAL TECHNOLOGIES CORPORATION

Dated: August 27, 2026

By:

/s/ David

Rosa

David Rosa

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED AUGUST 27, 2026

EX-99.1

Filename: ea030353001ex99-1.htm · Sequence: 2

Exhibit

99.1

NeuroOne

Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED™ Platform

Successful

Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies

Later This Quarter

StereoCED™ Revenue Expected to be Recognized in the Current Fiscal Quarter

EDEN

PRAIRIE, Minn. – August 27, 2026 – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or

the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological

disorders, today reported the successful completion of three separate large-animal procedures using its next-generation StereoCED™

platform. In two of the three procedures, NeuroOne’s drug delivery electrodes both delivered a study agent directly into targeted

brain tissue and recorded intracranial electrophysiological activity from the same targeted regions. This is a combination the Company

believes has not been previously demonstrated and represents a first in the field of convection-enhanced delivery.

The

procedures took place at the University of Minnesota as part of an ongoing preclinical epilepsy research program evaluating StereoCED™

for targeted drug delivery and electrophysiological monitoring in the brain. They were designed to establish technical feasibility and

validate the integrated surgical and drug delivery workflow in a large-animal model.

During

the procedures, researchers used a robotic platform to establish the planned trajectory, drill the access point, and place NeuroOne’s

anchor bolt. The Company’s drug delivery electrode and catheter were then advanced to the targeted region of the brain, where the

system delivered the study agent directly into targeted tissue.

NeuroOne

believes the successful repeatability demonstrated across three procedures provides additional confidence as the Company advances toward

the planned launch of StereoCED™ for human investigational clinical studies later this quarter.

Development

of StereoCED™ devices for animal use finished ahead of schedule, which allowed the Company to begin sales earlier than anticipated.

NeuroOne expects to recognize the related StereoCED™ revenue from this research program in fiscal Q4 2026. Development of devices

for human investigational use remains on track, with release planned by the end of fiscal Q4 2026.

“These

procedures accomplished our goals from a technical feasibility standpoint and build on the thousands of successful human sEEG implantations

from our epilepsy franchise,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “Our technology was successfully

implanted using a robotic workflow, drug delivery performed as intended, and in two cases high-quality electrophysiological recordings

were obtained. With the core technology and workflow now demonstrated in a large-animal model, we believe we have taken an important

step toward the planned launch of the StereoCED™ platform for human investigational clinical studies later this quarter.”

Dr.

Sandipan Pati, Professor and Epilepsy Division Director at the University of Minnesota, added, “These successful procedures represent

a key step in translating targeted intracerebral drug delivery from concept toward a potential therapeutic approach for patients with

epilepsy. Looking ahead, our research will focus on evaluating whether therapeutic agents delivered directly into seizure-generating

brain networks can modulate and suppress seizure activity. Ultimately, we believe this approach could enable more precise and individualized

treatment while minimizing the systemic exposure and off-target effects associated with conventional drug delivery.”

About

NeuroOne

Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients

suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology

platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for

brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations

and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged

in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information,

visit nmtc1.com.

Forward

Looking Statements

This

press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in

this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are

subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance

or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases,

you can identify forward–looking statements by the words or phrases “may,” “might,” “will,”

“could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,”

“anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,”

“target,” “seek,” “contemplate,” “continue, “focused on,” “committed to”

and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the

future. Forward–looking statements may include statements regarding the recognition of the first StereoCED™ revenue, the

timing of commercial sales, and the development for human investigational use. Although NeuroOne believes that we have a reasonable basis

for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known

by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from

what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization

or market acceptance of our technology; risks that our technology will not

perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s

capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure

or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology;

risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated

the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights;

and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings

with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and

NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes

available in the future.

Contact

Group – MZ North America

NMTC@mzgroup.us

EVO

sEEG-RF Electrode – Caution: Federal law restricts this device to sale by or on the order of a physician

Disclaimer: NeuroOne’s StereoCED™ Drug Delivery System is not approved/cleared for commercial use by any Regulatory agency.

GRAPHIC

Filename: ea030353001_ex99-1img1.jpg · Sequence: 3

Binary file (2410 bytes)

Download ea030353001_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 27, 2026

Entity File Number

001-40439

Entity Registrant Name

NeuroOne Medical Technologies Corporation

Entity Central Index Key

0001500198

Entity Tax Identification Number

27-0863354

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7599 Anagram Dr.

Entity Address, City or Town

Eden Prairie

Entity Address, State or Province

Entity Address, Postal Zip Code

55344

City Area Code

952

Local Phone Number

426-1383

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

NMTC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration